I agree that this site is using cookies. You can find further informations here.
X
Chyla, Brenda J
91  results:
Search for persons X
?
1

Six-year follow-up and subgroup analyses of a phase 2 trial..:

Stilgenbauer, Stephan ; Tausch, Eugen ; Roberts, Andrew W....
Blood Advances.  8 (2024)  8 - p. 1992-2004 , 2024
Link: https://doi.org/10.1182/..
 
?
2

Activity of venetoclax in patients with relapsed or refract..:

Kater, Arnon P ; Arslan, Önder ; Demirkan, Fatih...
The Lancet Oncology.  25 (2024)  4 - p. 463-473 , 2024
Link: https://doi.org/10.1016/..
 
?
3

Long‐term follow‐up of VIALE‐A: Venetoclax and azacitidine ..:

Pratz, Keith W. ; Jonas, Brian A. ; Pullarkat, Vinod...
American Journal of Hematology.  99 (2024)  4 - p. 615-624 , 2024
Link: https://doi.org/10.1002/..
 
?
4

A phase 1b study of venetoclax and alvocidib in patients wi..:

Jonas, Brian A. ; Hou, Jing‐Zhou ; Roboz, Gail J....
Hematological Oncology.  41 (2023)  4 - p. 743-752 , 2023
Link: https://doi.org/10.1002/..
 
?
5

P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC ..:

Konopleva, Marina ; D. Dinardo, Courtney ; Sun, Yan...
HemaSphere.  7 (2023)  S3 - p. e160928c , 2023
Link: https://doi.org/10.1097/..
 
?
6

POSTER: MPN-498 Addition of Navitoclax to Ruxolitinib for M..:

Pemmaraju, Naveen ; Somervaille, Tim C.P. ; Palandri, Francesca...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S193 , 2023
Link: https://doi.org/10.1016/..
 
?
7

AML-095 Findings From an Analysis of Patients With Monocyti..:

Konopleva, Marina ; DiNardo, Courtney ; Sun, Yan...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S266-S267 , 2023
Link: https://doi.org/10.1016/..
 
?
8

Author Correction: Transcriptomic profiles and 5-year resul..:

Al-Sawaf, Othman ; Zhang, Can ; Jin, Hyun Yong...
Nature Communications.  14 (2023)  1 - p. , 2023
Link: https://doi.org/10.1038/..
 
?
9

POSTER: AML-095 Findings From an Analysis of Patients With ..:

Konopleva, Marina ; DiNardo, Courtney ; Sun, Yan...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S156 , 2023
Link: https://doi.org/10.1016/..
 
?
10

Transcriptomic profiles and 5-year results from the randomi..:

Al-Sawaf, Othman ; Zhang, Can ; Jin, Hyun Yong...
Nature Communications.  14 (2023)  1 - p. , 2023
Link: https://doi.org/10.1038/..
 
?
11

Measurable residual disease in Japanese patients with relap..:

Izutsu, Koji ; Yamamoto, Kazuhito ; Kato, Koji...
International Journal of Hematology.  118 (2023)  4 - p. 526-528 , 2023
Link: https://doi.org/10.1007/..
 
?
12

P418: DELE1 LOSS AND DYSFUNCTIONAL INTEGRATED STRESS SIGNAL..:

Sharon, David ; Jung, Paul ; Sun, Yan...
HemaSphere.  7 (2023)  S3 - p. e7041879 , 2023
Link: https://doi.org/10.1097/..
 
?
13

S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALY..:

Kater, Arnon ; Harrup, Rosemary ; Kipps, Thomas J...
HemaSphere.  7 (2023)  S3 - p. e492813f , 2023
Link: https://doi.org/10.1097/..
 
?
14

MPN-498 Addition of Navitoclax to Ruxolitinib for Myelofibr..:

Pemmaraju, Naveen ; Somervaille, Tim C.P. ; Palandri, Francesca...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S396-S397 , 2023
Link: https://doi.org/10.1016/..
 
?
15

Relationship Between Venetoclax Exposure and Undetectable M..:

Gopalakrishnan, Sathej ; Menon, Rajeev ; Suleiman, Ahmed A....
HemaSphere.  7 (2023)  12 - p. e983 , 2023
Link: https://doi.org/10.1097/..
 
1-15